Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter clinical trial to investigate the safety and
efficacy of tislelizumab when given in combination with nab-paclitaxel as neoadjuvant
treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or
complete TURBT. Patients will receive neoadjuvant treatment with tislelizumab in combination
with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by radical
cystectomy or complete TURBT.